Clinical Trial Finder

Key

Inclusion Criteria:

1. Ability to understand and willingness to provide written informed consent to participate in this study. 2. ≥12 years of age. 3. Diagnosis: 1. Maintenance treatment cohort: Histologic or cytologic diagnosis of Ewing's sarcoma, including non-resected, locally advanced or metastatic disease. 2. Salvage treatment cohort: Non-resected, locally advanced or metastatic sarcoma (including Ewing's sarcoma) for which there is no standard of care treatment and no curative other option. 4. Radiographic disease assessment within 35 days prior to enrollment and planned treatment start with study drug. 5. Prior treatment: 1. Maintenance treatment cohort : 1-3 prior lines of systemic treatment (including current treatment) 2. Salvage cohort: Any number of prior treatments. 6. Maintenance treatment cohort only: Patient completed current line of treatment (systemic, surgery, radiation) prior to enrollment, without disease progression as compared to baseline AND has achieved at least one of the following. 1. CR in response to current second or third line treatment. 2. PR in response to current line of treatment (after at least 4 cycles, if treatment included systemic therapy) 3. SD in response to current line of treatment (after at least 4 cycles, if treatment included systemic therapy) 7. Measurable disease, except for patients in Cohort A who have achieved CR at the conclusion of current 2nd or 3rd line of treatment. 8. ECOG performance status 0-2. 9. Adequate organ function defined as all laboratory parameters ≤ Grade 2 NCI CTCAE criteria. 10. Patients must be able to swallow and retain whole capsules.Key

Exclusion Criteria:

1. Systemic anticancer agents within 14 days prior to treatment on study. 2. Major surgery within 30 days. 3. Prior treatment with SM-88. 4. Any screening laboratory, electrocardiogram (ECG), other clinical finding, comorbidity or clinical history that, in the opinion of the investigator, indicates an unacceptable risk for patient to participate in the study or would limit patient's ability to comply with study requirements. 5. History of any drug allergies or significant adverse reactions to any of the components of SM-88. 6. History of light sensitive diseases for which methoxsalen would be contraindicated. 7. Current or anticipated treatment with a contraindicated medication. 8. Evidence of viral infections including human immunodeficiency virus (HIV), hepatitis B, and hepatitis C

This prospective, open-label, two stage, pilot phase 2 trial evaluates the efficacy and safety of SM-88 in two cohorts of patients: 1) as maintenance therapy following standard primary or palliative treatments for Ewing's sarcoma patients with high risk of relapse or disease progression; and 2) as salvage therapy for patients with clinically advanced sarcomas. The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer treatment, measured as positive efficacy events, including overall response, maintaining stable disease for ≥ 3 months, or progression free survival at least 1.5 times longer than the last prior line of treatment. Eligible patients will receive daily oral treatment with SM-88, which consists of D,L-alpha-metyrosine, used with methoxsalen, phenytoin, and sirolimus in continuous treatment cycles of 28 days. Treatment will continue until: 1) Symptomatic, clinical progression with radiographic progressive disease; 2) 48 weeks after documented complete response; or 3) evidence of unacceptable toxicity, or other decision to discontinue treatment

Arms

Experimental: Maintenance Treatment: Ewing's Sarcoma

Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus

Experimental: Salvage Treatment: Sarcoma

Combination metyrosine-derivative, low-dose methoxasalen, phenytoin and sirolimus

Interventions

Drug: - Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)

Daily oral combination therapy for cancer